NAT2 rs1495741 and anti-tuberculosis drug-induced liver injury in children: genetic association and risk prediction
Chengxian Guo
BackgroundAnti-tuberculosis drug-induced liver injury (ATB-DILI) is a major adverse event in children receiving anti-tuberculosis therapy, but pediatric pharmacogenetic evidence remains limited.MethodsWe studied 192 children receiving anti-tuberculosis treatment, including 31 with ATB-DILI and 161 without DILI. After quality control, 86 single-nucleotide polymorphisms were tested for association with ATB-DILI. Based on three available NAT2 variants, NAT2 diplotypes were inferred from the genotyp